{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:49:56Z","timestamp":1782247796722,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011123","name":"University of Minnesota Academic Health Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27567","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:20:24Z","timestamp":1709817624000},"page":"e27567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-4729","authenticated-orcid":false,"given":"Kathleen","family":"Mahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3423-5890","authenticated-orcid":false,"given":"Sarah","family":"Kiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-4231","authenticated-orcid":false,"given":"Rebecca","family":"Freese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Marka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-289X","authenticated-orcid":false,"given":"Jordan","family":"Dunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-4057","authenticated-orcid":false,"given":"Joanne","family":"Billings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.heliyon.2024.e27567_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27567_bib2","unstructured":"Centers for Disease Control and Prevention. CDC COVID Data Tracker Atlanta, GA: US Department of Health and Human Services. https:\/\/covid.cdc.gov\/covid-data-tracker.."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2013.06.004","article-title":"The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation","volume":"13","author":"Etherington","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27567_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1183\/09031936.00202311","article-title":"Viral infections trigger exacerbations of cystic fibrosis in adults and children: figure 1","volume":"40","author":"Wark","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27567_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1165\/rcmb.2011-0399RT","article-title":"Immune responses in cystic fibrosis: are they intrinsically defective?","volume":"46","author":"Ratner","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27567_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccm.2022.06.004","article-title":"Update on innate and adaptive immunity in cystic fibrosis","volume":"43","author":"Bruscia","year":"2022","journal-title":"Clin. Chest Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27567_bib7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2021.03.017","article-title":"Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between february and june 2020","volume":"20","author":"Naehrlich","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27567_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jcf.2020.08.005","article-title":"SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis","volume":"19","author":"Berardis","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27567_bib9","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jcf.2021.12.011","article-title":"SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: a seroprevalence study in two specialized centres in Northern Italy","volume":"21","author":"Alicandro","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e27567_bib10","series-title":"SARS-CoV-2 Infection in Cystic Fibrosis: A Multicentre Prospective Study with a Control Group","author":"Colombo","year":"2021"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27567_bib11","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/ppul.26528","article-title":"Seroprevalence and clinical characteristics of SARS\u2010CoV\u20102 infection in children with cystic fibrosis","volume":"58","author":"Hergenroeder","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.heliyon.2024.e27567_bib12","unstructured":"Mn Department of Health. COVID-19 Vaccine Data St. Paul, MN. https:\/\/www.health.state.mn.us\/diseases\/coronavirus\/stats\/vaccine.html.."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e27567_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.15585\/mmwr.mm7222a3","article-title":"Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status \u2014 United States, April 2021\u2013september 2022","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e27567_bib14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.15585\/mmwr.mm7117e3","article-title":"Seroprevalence of infection-induced SARS-CoV-2 antibodies \u2014 United States, september 2021\u2013february 2022","volume":"71","author":"Clarke","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e27567_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.15585\/mmwr.mm7025e1","article-title":"COVID-19 vaccination coverage among adults \u2014 United States, december 14, 2020\u2013may 22, 2021","volume":"70","author":"Diesel","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","article-title":"Population antibody responses following COVID-19 vaccination in 212,102 individuals","volume":"13","author":"Ward","year":"2022","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e27567_bib17","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e27567_bib18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27567_bib19","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12890-022-01900-8","article-title":"One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis","volume":"22","author":"Jaudszus","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27567_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37257","article-title":"Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27567_bib22","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jcf.2022.06.006","article-title":"Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: a global observational study","volume":"21","author":"Carr","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12890-021-01528-0","article-title":"Systematic review: cystic fibrosis in the SARS-CoV-2\/COVID-19 pandemic","volume":"21","author":"Mathew","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41467-023-35862-0","article-title":"SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation","volume":"14","author":"Bezzerri","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27567_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41435-020-0103-y","article-title":"COVID-19 meets Cystic Fibrosis: for better or worse?","volume":"21","author":"Peckham","year":"2020","journal-title":"Gene Immun."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27567_bib26","doi-asserted-by":"crossref","first-page":"L408","DOI":"10.1152\/ajplung.00225.2020","article-title":"SARS-CoV-2 (COVID-19) and cystic fibrosis","volume":"319","author":"Stanton","year":"2020","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27567_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","article-title":"Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations","volume":"11","author":"Parotto","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27567_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27567_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/diagnostics12010137","article-title":"First case of COVID-19 treated with monoclonal anti-spike antibodies in a patient with cystic fibrosis in Romania","volume":"12","author":"Stan","year":"2022","journal-title":"Diagnostics"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024035989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024035989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:21:57Z","timestamp":1782246117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024035989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024035989"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27567","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27567"}}